Anti CD40 chlamydia vaccine - LinKinVax
Alternative Names: Anti CD40 CHLAMYDIA vaccine; ANTI-CD40 CHLAMYDIA vaccineLatest Information Update: 23 Mar 2022
At a glance
- Originator Vaccine Research Institute
- Developer LinKinVax
- Class Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Chlamydial infections
Most Recent Events
- 14 Mar 2022 LinKinVax plans to launch chlamydia vaccine for chlamydial infections by 2027 (LinKinVax pipeline, March 2022)
- 14 Mar 2022 New profile from LinKinVax pipeline, March 2022
- 03 Feb 2022 LinKinVax entered an exclusive worldwide licensing agreement with Inserm Transfert to develop vaccine strategy for HIV, SARS-CoV-2, human papillomavirus-related cancers, and chlamydia infections